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A B S T R A C T
Introduction: Thrombosis is a severe and frequent complication of heparin-induced thrombocytopenia (HIT).
However, there is currently no knowledge of the effects of HIT-like antibodies on the resulting microstructure of
the formed clot, despite such information being linked to thrombotic events. We evaluate the effect of the
addition of pathogenic HIT-like antibodies to blood on the resulting microstructure of the formed clot.
Materials and methods: Pathogenic HIT-like antibodies (KKO) and control antibodies (RTO) were added to
samples of whole blood containing Unfractionated Heparin and Platelet Factor 4. The formed clot microstructure
was investigated by rheological measurements (fractal dimension; df) and scanning electron microscopy (SEM),
and platelet activation was measured by flow cytometry.
Results and conclusions: Our results revealed striking effects of KKO on clot microstructure. A significant dif-
ference in df was found between samples containing KKO (df = 1.80) versus RTO (df = 1.74; p < 0.0001). This
increase in df was often associated with an increase in activated platelets. SEM images of the clots formed with
KKO showed a network consisting of a highly branched and compact arrangement of thin fibrin fibres, typically
found in thrombotic disease. This is the first study to identify significant changes in clot microstructure formed in
blood containing HIT-like antibodies. These observed alterations in clot microstructure can be potentially
exploited as a much-needed biomarker for the detection, management and monitoring of HIT-associated
thrombosis.
1. Introduction
Heparin-induced thrombocytopenia (HIT) associated thrombosis is
an adverse reaction to heparin therapy with an associated mortality rate
of approximately 20% [1]. Rapid and accurate diagnosis is crucial as
false diagnosis can expose thrombocytopenic patients to alternative
anticoagulants resulting in a risk of major bleeding [2,3]. In HIT, ne-
gatively charged heparin polysaccharides bind to positively charged
Platelet Factor 4 (PF4) released by activated platelets to form ultra-
large complexes (ULCs). ULCs are then identified as an antigen by the
immune system, leading to the production of specific antibodies that
bind to these ULCs and activate platelets, monocytes and other vascular
cells through FcγRIIA [1,4]. Monocyte activation leads to the expres-
sion of tissue factor and subsequent generation of thrombin, and acti-
vated platelets release additional stores of PF4, which not only
perpetuates the cycle but creates the extreme pro-thrombotic environ-
ment in which blood clots associated with HIT are formed [2,5,6].
Abnormal fibrin clot microstructure is widely reported to play an
important role in the pathophysiology of pro-thrombotic disease and
has clinical implications in the diagnosis and treatment of thrombosis
[7]. For example, samples of blood obtained from pro-thrombotic pa-
tients, such as patients with premature coronary arterial disease, ve-
nous thromboembolism, and ischemic stroke, have been demonstrated
to produce “abnormal” clots with a more compact fibrin network of
relatively thin, highly branched fibres [8–10]. Moreover, a structural
biomarker of haemostasis, the fractal dimension, has detected abnormal
clotting in patients with venous thromboembolism, despite those pa-
tients being administered warfarin [11]. However, microstructural
studies of blood clots associated with HIT have not been reported, even
though such analysis could be informative for understanding and
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potentially diagnosing the thrombosis accompanying HIT. Herein we
investigate fibrin clot microstructure in whole blood clots formed in the
presence of KKO, a known pathogenic HIT-like monoclonal antibody to
PF4-heparin [2,6,12,13]. We hypothesize that the presence of KKO will
produce results characteristic of other thrombotic conditions.
2. Methods
2.1. Blood samples and the HIT model system
Samples of whole human blood were obtained using a cohort of five
healthy individuals under full ethical approval and with informed
written consent (REC No. 13/WA/0190). Blood was collected from the
median cubital vein using a 21-gauge butterfly line (Greiner Bio One).
The first few ml of blood was collected via an additive free Vacuette®
and subsequently discarded in order to ensure that minimal tissue
factor was present. 10 ml of blood was collected and carefully ejected
into a sterile plastic universal bijou container containing no antic-
oagulant [14]. Samples were mixed with Unfractionated Heparin (UFH)
(Sigma-Aldrich) at a therapeutically relevant concentration of 0.5 U/ml
[15]. In the first part of the study, the samples were then mixed with a
solution of PF4 (0 μg/ml–60 μg/ml) in Tris-buffered saline to find the
optimal concentration of PF4 to bind to and neutralize the effects of
UFH. Five samples of blood were used for each concentration of PF4
(n = 5). In the second part of the study, samples of blood from each of
the five healthy volunteers were obtained on three separate occasions
(n = 15). Samples at the PF4 concentration that neutralized the heparin
effect were then prepared and divided into two aliquots. Pathogenic
KKO monoclonal antibodies (100 μg/ml) were added to one aliquot and
non-pathogenic RTO (100 μg/ml) monoclonal IgG antibodies, which
bind to PF4 independent of heparin, were added to the other aliquot as
a control [12]. 1.2 ml of each sample was used immediately for rheo-
logical analysis. 1 ml of each sample was allowed to clot in a 9 well
sterile plate for imaging by scanning electron microscopy. A further
1 ml of each sample was anticoagulated using sodium citrate (3.8%),
with a 1:9 ratio of citrate to blood, for flow cytometry.
2.2. Rheology
The gel point of samples was measured using an AR-G2 Rheometer
(TA Instruments, UK). 1.2 ml of each sample was carefully pipetted
onto a 60 mm parallel plate geometry of an AR-G2 Rheometer (TA
Instruments, UK) with the lower plate controlled at a temperature of
37 °C by means of a Peltier unit. The gap was set to 380 μm, com-
mensurate to the value of the gap used in the study of Evans et al. [14].
A low viscosity silicone oil was used to seal the sample in order to
minimize evaporation at the sample edge. The values of storage moduli
G' and loss moduli G" of the sample during coagulation were monitored
over a frequency range of 0.2 to 2 Hz (using four discrete frequencies)
by the application of small amplitude oscillatory shear. The absence of a
third harmonic response confirmed that measurements were conducted
within the linear viscoelastic range (Fig. 1). At the gel point, G' and G"
exhibit a power law dependence on frequency of oscillation, and the
phase angle δ (= tan−1 (G"/G') is frequency independent. The gel point
signifies the transition from viscoelastic liquid-like behavior to viscoe-
lastic solid-like behavior, and therefore provides an unequivocal mea-
surement of clotting time in terms of the clot's haemostatic functionality
[11,14]. Furthermore, the values of the phase angle at the gel point
permits calculation of the fractal dimension, df, a structural parameter
used to quantify the structure and complexity of the fibrin network of
each sample [11,14,16,17]. In the case of the experiments involving the
two antibodies, samples prepared from the same blood were tested si-
multaneously using two AR-G2 rheometers. Computer generated
random fractal aggregates utilizing a box counting approach produced a
visual illustration of the incipient clot microstructure corresponding to
the experimental clots, based on the df obtained from rheology [18].
2.3. Scanning electron microscopy
Samples were allowed to clot and prepared for microscopy and
subsequent image analysis using the following procedures. To remove
excess salt, the specimens were washed 3 times, in 10–20 min intervals,
by permeation with 50 mM sodium cacodylate buffer solution (Spi
Supplier, West Chester, PA, USA) at pH 7.4. The samples were then
fixed overnight in 2% glutaraldehyde (Sigma-Aldrich Ltd., UK), after
which they were washed in distilled water and then dehydrated using a
series of increasing ethanol concentrations (30–100%), over a period of
3.5 h. The dehydrated samples were rinsed with 100% hexamethyldi-
silazane (Sigma-Aldrich Ltd., UK) solution three times and left over-
night to dry. The sample was then coated with gold‑palladium using
sputter coating and imaged by SEM (Hitachi 4800 S, Hitachi High-
Technologies Pte Ltd., Singapore). Several areas of each clot were ex-
amined before choosing fields containing the fibrin network that were
most representative of those found in the entire clot. Digitized electron
micrographs were taken at 10 kV at magnifications of 4000 and 10,000.
The fibre diameter distribution was analysed using Image J (National
Institutes of Health) by placing a random grid of crosses (500 crosses/
image) on images and using the line tool to measure fibre diameter
[19]. 20 images at each magnification were used to provide histograms
of fibre diameter for each clot.
2.4. Flow cytometry
Citrated samples of blood (20 μl per tube) were fixed and stained
with PE-conjugated anti-human CD62P (Bio-Rad Laboratories, Inc.) as a
marker for platelet activation [20]. After adding antibody to the blood
the samples were incubated on ice in the dark for 30 min. Red blood
cells were then lysed by adding 1.5 ml of BD FACS Lysing Solution (BD
Bioscience) to each sample for 10 min at room temperature followed by
centrifugation at 515g at 4 °C for 10 min. Cells were then washed twice
with 1.5 ml of FACS buffer (PBS, Life Technologies Ltd.,/0.2% FCS,
Fig. 1. Example of the results of a rheological measurement of coagulating
blood. The phase angle, δ, at four different frequencies is plot as a function of
time. The gel point, as detected by a frequency independent δ, indicates the
transition from viscoelastic liquid-like behavior to viscoelastic solid-like beha-
vior. The gel point provides two biomarkers of haemostasis (i) the clotting time,
based on the time to reach the gel point and (ii) the fractal dimension, df, which
can be calculated from the value of δ at the gel point, and provides a measure of
the structural complexity of the clot. The image (inset) is a computer generated
random fractal aggregate corresponding to the calculated value of df for the
experimental clots.
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Sigma-Aldrich and 0.05 sodium azide, Life Technologies Ltd.). 200 μl of
BD Stabilising Fixative (BD Bioscience) was added after the second
wash to each sample and stored at 4 °C overnight. A fluorescence minus
one approach was used to set analysis gates [21]. Sample was treated
with 4 μM of phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich) for
30 min were used as a positive control for CD62P expression [22,23].
All samples were acquired within 24 h of collection using a
Beckman Coulter Navios flow cytometer with the 488 nm laser and
585/42 filter. The platelet population was gated to include both pla-
telets in a resting and activated state using the forward scatter (FSC)
and side scatter (SSC) of the unstained and positive controls as guidance
and a total of 10,000 events within this gate were recorded. The data
were analysed in Kaluza 1.2 (Beckman Coulter, UK). Histograms were
used to report the percentage of CD62P positive activated platelet
events.
3. Results and discussion
3.1. The optimal concentration of PF4 to neutralize the effects of UFH
The addition of PF4 to heparinized blood without other inhibitors
(Fig. 2) revealed a characteristic bell-shaped curve similar to that seen
in previous reports where PF4 modulated the antigenicity of HIT
complexes [24]. The value of df was relatively low (df = 1.56 ± 0.108)
in heparinized blood without PF4 compared to the unadulterated blood
(df = 1.76 ± 0.046) and was similar to the value found in a previous
study involving the in vitro addition of heparin [14]. The addition of
increasing levels of PF4 led to a gradual increase of df up to a maximum
value (df = 1.77 ± 0.028) at a PF4 concentration of 10 μg/ml; further
increasing levels of PF4 led to small decreases in df. A one-way ANOVA
test revealed that a PF4 concentration of 10 μg/ml produced a value of
df most similar (mean difference of 0.008) to that found in the un-
adulterated blood and also produced a df with the least variation. This
concentration of PF4 (10 μg/ml) is the optimal required for neutralizing
the effects of heparin and to promote the formation of ULCs necessary
to study the effects of HIT-like antibodies (henceforth, referred as the
HIT model system). Furthermore, the corresponding value of df
(1.77 ± 0.028) is not statistically significantly different (p = 0.26)
from the previously established healthy value (1.74 ± 0.050) [25].
The observed decrease in df at higher levels of PF4 may be due to excess
PF4 interacting with different proteins or increasing the positive charge
within the system and interfering with the coagulation process [26].
Excess amounts of PF4 have been reported to reduce the viscoelasticity
of the fibrin network that forms in platelet poor plasma and platelet rich
plasma, with saturating amounts of PF4 leading to a reduced porosity of
the fibrin network [27].
3.2. The HIT model system
The HIT model system using PF4, heparin and the HIT pathogenic
antibody KKO in whole blood revealed striking effects on clot micro-
structure as characterized by df. A significant difference (p < 0.0001)
was found between df in the samples containing the pathogenic anti-
body KKO and the non-pathogenic or blocking antibody RTO, con-
firming the hypothesis that clot structure is altered in blood containing
the pathogenic HIT-like antibodies (see Fig. 3a). Likewise, a significant
difference was found between df in samples containing KKO and the
neutralized samples of heparinized blood (p = 0.008). There was no
significant difference in df in samples containing RTO and the un-
adulterated blood (p = 0.16). The higher df value observed in samples
Fig. 2. The neutralization of heparin by PF4. Fractal dimension, df, of clots
formed in heparinized blood (0.5 U/ml) with various concentrations of PF4 (0
to 60 μg/ml). The optimal concentration of 10 μg/ml, as depicted by *, pro-
duces a clot with df most similar to that found in whole blood from the cohort of
volunteers.
Fig. 3. The thrombotic characteristics of clots as measured by rheology and flow cytometry. Measured values of (a) fractal dimension, df, (b) clotting time, and (c)
platelet activation, in samples of blood containing the non-pathogenic antibody RTO and the pathogenic antibody KKO (n = 15). Graphs are presented as box and
whisper plots, whereby a cross represents the mean value, circles represent individual data points, the shaded box represents the values bound by the upper and lower
quartile, the horizontal line represents the median value, and the bars (whiskers) represent the range. A significant difference in df (p < 0.00001) and activated
platelets (p = 0.0009) was found between samples containing the non-pathogenic RTO and the pathogenic KKO antibodies.
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containing KKO (df = 1.80 ± 0.024) is characteristic of abnormal
blood clots formed using blood obtained from patients with a throm-
botic condition [11,25,28]. It is pertinent to note here that the rela-
tively small differences observed in df correspond to large differences in
associated clot mass, as demonstrated by the computational generated
fractal aggregates that represent the modulation of clot structure (see
Fig. 4). The incipient clot formed at the gel point in the samples con-
taining KKO has an associated mass 2.5 times greater than that of the
RTO counterpart, signifying a much denser clot that is associated with
enhanced resistance to fibrinolysis [29]. Interestingly, there was no
difference observed in the clotting time in samples containing KKO and
RTO (p = 0.95, see Fig. 3b). In general, fibrin clots formed in shorter
times produce denser clots with more mass, but such a supposition has
not been fully explored and might not capture the full complexity of the
coagulation process in whole blood. Furthermore, our results suggest
that rate-based assays (such as activated partial thromboplastin time,
prothrombin time and thromboelastography or thromboelastometry)
have limited diagnostic value in the detection of thrombosis associated
with HIT.
The results of the flow cytometry revealed that levels of platelet
activation as measured by increased expression of CD62P were sig-
nificantly greater (p = 0.0009) in samples containing KKO versus RTO
(Fig. 3c) and increasing levels of platelet activation coincided with in-
creases in df. These results are compatible with the notion that the
presence of KKO leads to a pro-thrombotic environment, since KKO
antibodies are known bind to ULCs and the FcγRIIA-receptors found on
platelets, which in turn creates a thrombin burst that becomes self-
perpetuating [1,3]. Examination of the results from individual samples
showed that the levels of activated platelets in samples containing KKO
varied considerably between each donor leading to an observed high
degree of variability (illustrated in the box and whisker plot of Fig. 3c),
as shown previously [30,31]. In contrast, df showed little variation in
the presence of KKO and was consistently elevated. Moreover, there
was a small to moderate positive correlation between values of df and
platelet activation (Pearson coefficient value, r = 0.31) in the samples
containing KKO. A relatively large df coinciding with, in some cases, a
relatively small amount of platelet activation might be explained by the
interaction of the pathogenic antibody with other cells within the blood
sample. For example, studies have shown that HIT-like antibodies can
activate monocytes in the presence of PF4 and these activated mono-
cytes can express tissue factor, helping in generating procoagulant ac-
tivity [32].
Fig. 5 (upper) shows micrographs of blood clots formed at each
stage of the HIT model system obtained using SEM. The images were
selected as those most representative of the fibrin network of the entire
clot. Comparison of the images show progressive changes in the
structures of the underlying fibrin network, with a pattern consistent
with the rheology studies in that clots with more “dense” or “tight”
networks of fibrin fibres correspond to those with the largest values of
df. The addition of heparin leads to a more “open” or more porous fibrin
network (compared to the network formed in unadulterated whole
blood). The addition of PF4 to the heparinized blood produces a clot
fibrin network that is similar to the unadulterated blood clot. The ad-
dition of non-pathogenic anti-PF4 antibody RTO to the blood system
containing heparin and PF4 did not affect the structure significantly.
The images obtained from samples in the presence of HIT-like mono-
clonal KKO antibodies produced the most striking visual differences,
showing a network consisting of a highly branched and compact ar-
rangement of relatively thin fibrin fibres. The quantification of fibre
diameter as depicted in the histograms (Fig. 5, lower) show that the
presence of KKO produces clots made up of a higher proportion of
thinner (< 150 nm) fibres compared to the RTO control. Clots pro-
duced with KKO consist of 36% of fibres of diameter of< 150 nm, in
contrast to clots produced with RTO where 6% of fibres have diameter
Fig. 4. (upper) Illustration of the clot structures associated
with the measured fractal dimensions of the clots, from
computer generated random fractal aggregates corresponding
to (a) heparinized blood (0.5 U/ml), df = 1.56, (b) hepar-
inized blood (0.5 U/ml) with PF4 (10 μg/ml) and RTO anti-
bodies (100 μg/ml), df = 1.74 and (c) heparinized blood
(0.5 U/ml) with PF4 (10 μg/ml) and KKO antibodies (100 μg/
ml), df = 1.80. The fibrin network is depicted in green with
denser regions of fibrin in red. (lower) Representation of clot
mass for different stages of the HIT model system. Clot mass,
normalised to a df = 1.74 (RTO control), as a function of
fractal dimension. The non-linear relationship between mass
and fractal dimension illustrates that small changes in df re-
quires large increases in associated clot mass. The incipient
clot formed at the gel point in the samples containing KKO has
an associated mass 2.5 times greater than that of the RTO
counterpart. (For interpretation of the references to color in
this figure legend, the reader is referred to the web version of
this article.)
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of< 150 nm. Clots formed from dense networks of thinner fibres have
been consistently found in many thrombotic conditions [7–10,33,34].
Such clots are generally stiffer, have lower permeability and are more
resistant to fibrinolysis than clots made up of a sparse network of
thicker fibres [35,36] and are likely to contribute to the pro-thrombotic
phenotype in HIT.
4. Conclusions
In summary, we have shown that the presence of the pathogenic
HIT-like monoclonal antibody KKO, results in clots that are character-
istic of other thrombotic conditions. These observed alterations in clot
microstructure, as expressed by df, can be potentially exploited as a
structural biomarker for the detection, management and monitoring of
HIT-associated thrombosis. A future study will involve the assessment
of the diagnostic and prognostic value of measuring df in blood ob-
tained from patients undergoing heparin therapy.
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